靶向肿瘤新生血管唑来膦酸阳离子隐形脂质体抗肿瘤作用的研究

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (1): 33-36.

靶向肿瘤新生血管唑来膦酸阳离子隐形脂质体抗肿瘤作用的研究

陈芳君¹，王增¹，蔡鑫君²，曹莹莹¹，陈培¹，邵芸¹

¹浙江省肿瘤医院，²杭州市红十字会医院药剂科，杭州 310003，浙江

收稿日期:2016-09-06 修回日期:2016-11-01 出版日期:2017-01-26 发布日期:2017-01-23
通讯作者: 王增，硕士，主管药师，研究方向：肿瘤药学研究。 Tel：0571-88122120 E-mail：wangzeng@zjcc.org.cn
作者简介:陈芳君，女，本科，药师，研究方向：肿瘤药学研究。 E-mail：chenfj@zjcc.org.cn
基金资助:
浙江省医药卫生科技计划（2014KYB039）；浙江省中医药科技计划（2015ZA148, 2016ZA038，20172A109）；浙江省公益性技术应用研究计划项目（2015C33286）；杭州市医药卫生科技计划（201553365），浙江省肿瘤医院“1022”人才项目

Anti-tumor effects of zoledronic acid-loaded stealth cationic liposome by targeting tumor angiogenesis

CHEN Fangjun ¹, WANG Zeng ¹, CAI Xinjun², CAO Yingying¹, CHEN Pei ¹, SHAO Yun ¹

¹Department of Pharmacy, Zhejiang Cancer Hospital, ²Department of Pharmacy, the Red Cross Hospital of Hangzhou, Hangzhou 310003, Zhejiang, China

Received:2016-09-06 Revised:2016-11-01 Online:2017-01-26 Published:2017-01-23

摘要/Abstract

摘要：

目的:研究APRPG（Ala-Pro-Arg-Pro-Gly）修饰的隐形唑来膦酸阳离子脂质体对荷前列腺癌PC-3裸鼠的抗肿瘤作用。方法: 构建荷前列腺癌PC-3裸鼠模型，比较研究唑来膦酸阳离子脂质体、APRPG修饰的隐形唑来膦酸阳离子脂质体对肿瘤体积增长的抑制作用，计算肿瘤抑制率，并通过免疫组化实验分析其对肿瘤相关因子血管内皮生长因子（VEGF）和分化抗原簇44（CD44）表达的影响。结果: 唑来膦酸阳离子脂质体、APRPG修饰的隐形唑来膦酸阳离子脂质体对荷前列腺癌PC-3裸鼠的肿瘤抑制率分别为31.81%、68.18%，后者的肿瘤抑制率明显高于前者（P<0.05），免疫组化结果显示VEGF和CD44蛋白在模型对照组中表达呈强阳性，在唑来膦酸阳离子脂质体组中呈中度阳性表达，而在APRPG修饰的隐形唑来膦酸阳离子脂质体中表达较为微弱。结论:APRPG修饰的隐形唑来膦酸阳离子脂质体对前列腺癌PC-3裸鼠具有更强的肿瘤抑制率。

关键词: 肿瘤新生血管靶向, 唑来膦酸阳离子隐形脂质体, 抗肿瘤

Abstract:

AIM: To investigate the anti-tumor effect of APRPG modified zoledronic acid-loaded stealth cationic liposomes in nude mice bearing PC-3 prostate cancer. METHODS: Prostate cancer cell PC-3 beared nude mice model was constructed, growth inhibition of tumor volume between zoledronic acid cationic liposome and APRPG modificated zoledronic acid-loaded stealth cationic liposomes was compared, and the tumor inhibition rate was calculated. Immunohistochemistry analysis was used to detect the effect on expression of VEGF and CD44. RESULTS: The tumor inhibition rate of zoledronic acid cationic liposome and APRPG modificated zoledronic acid-loaded stealth cationic liposomes were 31.81%,68.18%, respectively, the tumor inhibition rate of the latter was significantly higher than that of the former (P<0.05), immunohistochemical results showed that VEGF and CD44 protein expression was strong positive in the model control group, in zoledronic acid cationic liposome group, it showed a moderate positive expression, and in APRPG modificated zoledronic acid-loaded stealth cationic liposomes group, the expression was very weak. CONCLUSION: The APRPG modified stealth liposome can exert a stronger inhibition effect in PC-3 nude mice.

Key words: targeting tumor angiogenesis, zoledronic acid-loaded stealth cationic liposomes, anti tumor

中图分类号:

R965.2

陈芳君，王增，蔡鑫君，曹莹莹，陈培，邵芸. 靶向肿瘤新生血管唑来膦酸阳离子隐形脂质体抗肿瘤作用的研究[J]. 中国临床药理学与治疗学, 2017, 22(1): 33-36.

CHEN Fangjun, WANG Zeng, CAI Xinjun, CAO Yingying, CHEN Pei, SHAO Yun. Anti-tumor effects of zoledronic acid-loaded stealth cationic liposome by targeting tumor angiogenesis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 33-36.

参考文献

［1］Zhao X, Hu X. Dosing of zoledronic acid with its anti-tumor effects in breast cancer［J］. J Bone Oncol, 2015, 4(3): 98-101.
［2］Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients［J］. Clin Cancer Res, 2003, 9(8): 2893-2897.
［3］Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates［J］. J Transl Med, 2011, 9: 177.
［4］De Luca A, Lamura L, Gallo M, et al. Pharmacokinetic evaluation of zoledronic acid［J］. Expert Opin Drug Metab Toxicol, 2011, 7(7): 911-918.
［5］Riebeline C, Forsea AM, Raisova M, et al.The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro［J］. Br J Cancer, 2002, 87(3): 366-371.
［6］Lu ZX, Liu LT, Qi XR. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy［J］. Int J Nanomedicine, 2011, 6: 1661-1673.
［7］Cai XJ, Wang Z, Wang CY, et al. In vitro and in vivo evaluation of cationic liposomes containing zoledronic acid as anticancer agent［J］. Latin Am J Pharm, 2015, 34(6): 1239-1245.
［8］Honda M, Asai T, Oku N, et al. Liposomes and nanotechnology in drug development: focus on ocular targets［J］. Int J Nanomedicine, 2013, 8: 495-503.
［9］Wang Y, Liu P, Duan Y, et al. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer［J］. Biomaterials, 2014, 35(3): 983-992.
［10］Barbera-Guillem E, Nyhus JK. Vascular endothelial growth factor secretion by tumor- infiltrating macrophages essentially supports tumor angioge- nesis, and IgG immune complexes potentiate the process［J］. Cancer Res, 2002, 62 (23): 7042-7049.
［11］Bozorgi A, KhazaeiI M, Khazaei MR. New findings on breast cancer stem cells: a review［J］. J Breast Cancer, 2015, 18(4): 303-312.

[1]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[2]	缪亚东, 李蹊, 王燕, 高坡, 周敏, 于浩. 抗肿瘤药物临床试验数据管理的一般考虑[J]. 中国临床药理学与治疗学, 2022, 27(9): 1055-1060.
[3]	陈宇罡, 屠艳琼, 王聪庆, 陈娟, 张博宏. 应用网络药理学和分子对接技术探讨金虎通胆汤治疗胆石症的作用机制及实验验证[J]. 中国临床药理学与治疗学, 2022, 27(10): 1090-1098.
[4]	邓颖, 白殊同. 金圣草黄素相关药理作用机制的研究进展 [J]. 中国临床药理学与治疗学, 2022, 27(10): 1155-1162.
[5]	邢晗，宁晨，孔德璇，蔡卉，周时雨，任畅，孔颖，程钰洁，陈西敬. 高抗肿瘤活性汉黄芩素衍生物GL-V9在大鼠体内的组织分布和排泄研究[J]. 中国临床药理学与治疗学, 2019, 24(8): 889-895.
[6]	郭丽，韩晨阳. 胡椒碱脂质体的制备及对于胃癌细胞体外抗肿瘤活性的作用研究[J]. 中国临床药理学与治疗学, 2018, 23(11): 1240-1245.
[7]	姚天怡, 尹少平, 刘雯, 赵炎磊, 王广基, 李娟. 紫杉醇聚合物胶束的组织分布和生物学评价[J]. 中国临床药理学与治疗学, 2017, 22(11): 1207-1214.
[8]	李晖，陈俊，徐彩虹，庞林荣，程晓春. 丹酚酸A抗肿瘤作用及对逆转A549/MTX肿瘤多药耐药的影响[J]. 中国临床药理学与治疗学, 2017, 22(11): 1244-1247.
[9]	邓俊丽，张蕊，唐洁，王果，朱院山. 他汀类药物抗肿瘤作用的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(1): 92-99.
[10]	吕子强，吕紫阳，马成华，马晓成，马小罕，涂志. 组蛋白去乙酰化酶抑制剂联合用药研究进展[J]. 中国临床药理学与治疗学, 2016, 21(5): 579-585.
[11]	马蔚蔚. 研究护士在抗肿瘤药物临床试验中的地位和影响[J]. 中国临床药理学与治疗学, 2016, 21(2): 178-180.
[12]	连燕娜，高丽萍. 益气补肾方药对顺铂致大鼠肾毒性及顺铂抗肿瘤活性的影响[J]. 中国临床药理学与治疗学, 2016, 21(1): 50-54.
[13]	陈焱, 叶斌, 莫文元, 俞诚波, 林晡, 尹向鹏, 许红苗. 抗肿瘤坏死因子单抗对脂多糖诱导的人牙周膜成纤维细胞TRAIL和TNF-α的影响[J]. 中国临床药理学与治疗学, 2015, 20(5): 493-498.
[14]	尚利娜, 洪明岳. 抗肿瘤抗生素抗体靶向药物研究新进展[J]. 中国临床药理学与治疗学, 2014, 19(9): 1075-1080.
[15]	张军, 崔亚放, 张昌卓, 张亚, 邵鹏. 乙酰肝素酶靶点药物的抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2014, 19(8): 953-960.